Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Neurol Neurosurg ; 191: 105675, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-31954364

RESUMO

OBJECTIVE: Epidural steroid injections (ESIs) are a commonly used treatment strategy for low back pain and lumbar radiculopathy. However, their cost-effectiveness and ability to mediate long-term quality of life (QOL) improvements is debated. We sought to analyze the cost-effectiveness of lumbar epidural steroid injections (ESIs) compared to medical management alone for patients with lumbar radiculopathy and low back pain. PATIENTS AND METHODS: QOL outcomes were prospectively collected at 3- and 6-months following initial consultation. Metrics included the EuroQol-5 Dimensions (EQ-5D) questionnaire, the Pain Disability Questionnaire (PDQ), the Patient Health Questionnaire (PHQ-9) and the Visual Analogue Scale (VAS). Cost estimations were based on Medicare national payment amounts, median income, and missed workdays. A cost-utility analysis was performed based upon cost estimations and a cost-effectiveness threshold of $100,000/Quality-adjusted life year (QALY). RESULTS: One hundred forty-one patients met our inclusion/exclusion criteria; 89 received ESI and 52 were treated with medical management alone. Both cohorts showed improved EQ-5D scores at 3 months but were similar to one another: ESI (ΔEQ-5D = 0.06; p = 0.03) and medical-alone (ΔEQ-5D = 0.07; p = 0.03). No significant difference was seen between groups for total costs ($2,190 vs. $1,772; p = 0.18) or cost-utility ratios ($38,710/QALY vs. $27,313/QALY; p = 0.73). At both the 3-month and 6-month endpoints, absolute differences in cost-utility was driven by overall costs as opposed to QALY gains. Medical management alone was more cost effective at both points owing to lower expenditures, however these differences were not significant. No benefits were seen in either group on the EQ-5D or any of the patient reported outcomes at the 6-month time point. CONCLUSION: ESIs were not cost-effective at either the 3-month or 6-month follow-up period. At 3 months, ESIs provide similar improvements in QOL outcomes relative to medical management and at similar costs. At 6 months, neither ESIs nor conservative management provide significant improvements in QOL outcomes.


Assuntos
Analgésicos não Narcóticos/uso terapêutico , Analgésicos Opioides/uso terapêutico , Glucocorticoides/administração & dosagem , Injeções Epidurais/economia , Dor Lombar/terapia , Fármacos Neuromusculares/uso terapêutico , Radiculopatia/terapia , Idoso , Tratamento Conservador , Análise Custo-Benefício , Feminino , Humanos , Degeneração do Disco Intervertebral/complicações , Dor Lombar/economia , Dor Lombar/etiologia , Dor Lombar/fisiopatologia , Vértebras Lombares , Masculino , Pessoa de Meia-Idade , Medição da Dor , Questionário de Saúde do Paciente , Modalidades de Fisioterapia , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Radiculopatia/economia , Radiculopatia/etiologia , Radiculopatia/fisiopatologia , Estenose Espinal/complicações , Espondilose/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA